鱼腥草滴眼液治疗流行性角膜结膜炎的临床观察

目的:观察鱼腥草滴眼液治疗流行性角膜结膜炎的临床效果。方法:收集2005-07/2005-09同仁医院门诊急诊就诊的临床确诊为流行性角膜结膜炎的患者40例,随机分为观察组和对照组,分别给予鱼腥草滴眼液和1g/L阿昔洛韦滴眼液点眼,观察6项眼部症状及体征的变化并评分,进行统计学分析。结果:在总的显效率上,两组间差异有统计学意义(P<0.01),观察组优于对照组。用药后第7d,在结膜充血的改善上观察组和对照组间差异有统计学意义(P<0.05);用药后14d,在畏光、异物感、流泪以及结膜充血的改善上两组差异均有统计学意义(P<0.05〉。结论:鱼腥草滴眼液对于治疗流行性角膜结膜炎有明显效果,其疗效优于1g/L阿昔洛韦滴眼液。     

加替沙星和左氧氟沙星对急性细菌性结膜炎有效性与安全性的Meta分析

目的:运用Meta分析系统评价加替沙星滴眼液和左氧氟沙星滴眼液对急性细菌性结膜炎的临床疗效及安全性。方法:按Cochrane系统评价方法,以“加替沙星”“左氧氟沙星”“急性细菌性结膜炎”为关键词,检索Embase、Cochrane library、Pubmed、Medline、中国知网数据库、万方数据库、维普中文科技期刊数据库、中国生物医学文献数据库,从建库开始时间检索至2021-03-01。纳入比较加替沙星滴眼液和左氧氟沙星滴眼液治疗急性细菌性结膜炎的随机对照研究。采用Cochrane偏倚风险评估工具对纳入研究进行质量评价,使用RevMan5.3统计软件进行Meta分析,运用Stata12中Egger检验分析发表性偏倚,并按照GRADE系统评估证据水平。结果:共纳入10项随机对照研究,合计1149例患者。对照组采用左氧氟沙星滴眼液治疗,试验组采用加替沙星滴眼液滴眼液治疗。Meta分析结果表明加替沙星滴眼液组对于急性细菌性结膜炎临床有效率优于左氧氟沙星滴眼液组(OR=3.75,95%CI:2.52~5.58,P<0.00001),Egger检验提示存在发表偏倚,且GRADE评价结果显示该证据水平为“很低”;加替沙星滴眼液组药物不良反应发生率低于左氧氟沙星滴眼液组(OR=0.37,95%CI:0.19~0.71,P=0.003);Egger检验提示不存在发表偏倚,且根据GRADE方法评价,该证据水平为“低”。结论:加替沙星滴眼液对于急性细菌性结膜炎的疗效优于左氧氟沙星滴眼液,且不良反应发生率较低;但由于纳入的研究证据水平较低,需要更多的多中心、随机双盲临床试验,从而提高加替沙星滴眼液治疗急性细菌性结膜炎临床疗效的证据强度。     

玻璃酸钠和重组牛bFGF滴眼液在角膜铁锈异物取出术后的疗效

目的:观察比较玻璃酸钠滴眼液和重组牛碱性成纤维细胞生长因子滴眼液联合应用对角膜铁锈异物取出术后角膜创面上皮修复的临床效果。方法:选择角膜铁锈异物患者98例98眼,随机分成联合治疗组49例49眼和对照组49例49眼。联合治疗组于角膜异物取出术后滴玻璃酸钠滴眼液+重组牛碱性成纤维细胞生长因子滴眼液+盐酸左氧氟沙星滴眼液;对照组滴重组牛碱性成纤维细胞生长因子滴眼液+盐酸左氧氟沙星滴眼液。每周3次观察角膜荧光素染色、角膜创面上皮修复及患眼局部症状等指标,观察2wk。结果:联合治疗组的总有效率96%高于对照组的88%(P<0.05)。结论:玻璃酸钠滴眼液和重组牛碱性成纤维细胞生长因子滴眼液联合应用能明显促进角膜损伤后上皮修复速度,疗效确切,安全可靠。     

富马酸依美斯汀联合氟米龙滴眼液治疗过敏性结膜炎

目的：评价富马酸依美斯汀滴眼液联合氟米龙滴眼液治疗过敏性结膜炎的疗效。

方法：回顾性研究。选取2020-06/2022-08于我院就诊接受治疗的过敏性结膜炎患者115例230眼,在常规使用富马酸依美斯汀滴眼液治疗的同时根据是否联合使用氟米龙滴眼液分为观察组(56例112眼)和对照组(59例118眼)。分别于治疗前、治疗4 wk后评估两组患者的眼部临床症状和体征评分、泪膜破裂时间(BUT)、角膜荧光素染色评分,并记录治疗期间并发症发生情况。

结果：治疗后两组患者眼部症状和体征评分均降低,且观察组低于对照组(P<0.05); 两组患者BUT均长于治疗前,且观察组长于对照组(P<0.05); 两组患者角膜荧光素染色评分均降低,且观察组低于对照组(P<0.05)。两组患者治疗期间并发症总发生率(3.6% vs 5.1%)无明显差异(P>0.05)。

结论：富马酸依美斯汀滴眼液联合氟米龙滴眼液治疗过敏性结膜炎可明显减轻患者的眼部症状与体征,延长泪膜破裂时间,降低角膜荧光素染色评分,提高疗效,且不增加并发症发生风险,安全性和有效性较高。     

鱼腥草滴眼液治疗急性卡他性结膜炎

目的观察鱼腥草滴眼液治疗急性卡他性结膜炎的疗效.方法观察组103例140眼采用鱼腥草滴眼液滴眼;对照组60例患者81眼予以3g@L-1氧氟沙星滴眼液滴眼,疗程7d.结果观察组总显效率53.6%,对照组45.7%,x2=1.027,P＞0.05;观察组有效率88.1%,对照组90.1%,x2=0.175,P＞0.05,2组比较无显著性差异.结论鱼腥草滴眼液对急性卡他性结膜炎有显著疗效,与3g@L-1氧氟沙星相似.     

聚乙二醇滴眼液联合重组牛碱性成纤维细胞生长因子治疗干眼症

目的:评价聚乙二醇滴眼液联合重组牛碱性成纤维细胞生长因子滴眼液治疗干眼症的疗效。方法:干眼症患者51例102眼,双眼自身对照,随机分为治疗组和对照组。治疗组给予聚乙二醇滴眼液和重组牛碱性成纤维细胞生长因子滴眼液,均4次/d,两种滴眼液之间间隔5～10min。对照组给予聚乙二醇滴眼液滴眼,4次/d,连续用药1mo后复查。观察每组用药前后SchirmerⅠ试验,BUT,角膜荧光素染色和症状改善情况。结果:两组治疗前后BUT,角膜荧光素染色和症状都有显著差异(P<0.05)。两组治疗前后SchirmerⅠ试验结果无显著差异(P>0.05)。治疗后两组BUT,角膜荧光素染色和症状也有显著差异(P<0.05)。结论:聚乙二醇滴眼液联合重组牛碱性成纤维细胞生长因子滴眼液对治疗干眼症有明显的疗效。     

角膜异物剔除术后贝复舒滴眼液对上皮愈合的作用

目的：探讨角膜异物剔除术后局部滴用贝复舒滴眼液的临床效果。方法：将147眼角膜异物剔除术后创面有浸润者随机分成2组，对照组69眼局部给予氧氟沙星滴眼液，治疗组78眼加用贝复舒滴眼液治疗，比较两组膜上皮愈合时间。结果：治疗组78眼中角膜上皮愈时时间＜24小时46眼，24－48小时22眼，＞48小时10眼；对照组69眼中角膜上皮愈合时间＜24小时10眼，24－48小时28眼，＞48小时31眼。两组比较，治疗组角膜皮皮愈合时间明显小于对照组（X^2检验,t＝32．843，P＜0．01）。结论：贝复舒滴眼液作为一种多功能细胞生长因子，能刺激角膜基质成纤维细胞增生移行并加速角膜上皮增生，可促进角膜多种组织的修复与再生，在角膜异物剔除术后角膜浸润面的愈合中对角膜上皮有修复作用。     

春季卡他性结膜炎的药物治疗疗效观察

目的临床观察0.1%盐酸奥洛他定滴眼液联合那素达滴眼液治疗春季卡他性结膜炎的疗效。方法对169例患者应用奥洛他定滴眼液滴眼2次/日,共1.5～3个月;那素达滴眼液3次/日点眼,共1个月。于治疗后3、7、14、28 d,2个月、3个月随访观察。结果联合用药后7 d 84.2%的结膜充血消失,14 d时79.7%的眼痒、烧灼感、畏光流泪等症状消失,3个月时治愈率达98.7%。结论奥洛他定联合那素达滴眼液可快速、持久稳定的控制春季卡他性结膜炎的症状及体征。     

环孢霉素A滴眼液治疗单疱病毒性角膜基质炎疗效观察

目的:观察10g/L环孢霉素A滴眼液治疗单疱病毒性角膜基质炎临床疗效。方法:我院2011-01/2012-01治疗单疱病毒性角膜基质炎患者91例91眼,随机分为两组,A组应用10g/L环孢霉素A滴眼液和更昔洛韦凝胶,B组应用5g/L氯替泼诺滴眼液和更昔洛韦凝胶,其余均为对症治疗,随诊观察6～12(平均10)mo。结果:两组治疗单疱病毒性角膜基质炎疗效无显著性差异,但A组治愈时间平均5.1±2.4d,B组治愈时间平均6.2±2.8d,A组较B组平均治愈时间短。两组治愈率及复发率无统计学差异。结论:对于单疱病毒性角膜基质炎患者应用10g/L环孢霉素A滴眼液能够安全有效治愈,且治愈时间短。     

盐酸氮卓斯汀滴眼液治疗儿童变态反应性结膜炎的疗效

观察氮卓斯汀滴眼液治疗儿童变态反应性结膜炎的临床疗效。 方法：变态反应性结膜炎患儿30例随机分为两组：对照组单用玻璃酸钠滴眼液,试验组联合应用玻璃酸钠滴眼液与05g/L盐酸氮卓斯汀滴眼液,治疗前后观察眨眼、眼痒症状、结膜水肿、结膜充血及上、下睑结膜乳头和滤泡、角膜缘腺样增生等体征,评价治疗有效率。 结果：对照组症状、体征评分治疗前后分别为4.60±0.87,472±1.53与2.53±1.45,2.40±1.20;试验组症状、体征评分治疗前后分别为4.72±0.77,5.29±1.46与1.47±1.48,1.59±1.12,两组差异有统计学意义（P<0.05）。对照组与试验组治疗后有效率分别为33%和73%,差异有统计学意义（P<0.05）。 结论：盐酸氮卓斯汀滴眼液是一种有效而安全的治疗儿童变态反应性结膜炎的药物     

Strabisme Alternant - Etude clinique - traitement

The author defines motor and sensory alternation: the term alternation should not be used in isolation, it should always be accompanied by the name of the parameter concerned. Sensory alternation is always found together with motor alternation but the reverse is not true.The examining criteria for a diagnosis of sensory alternation are given, sensory alternation must not be confused with alternating inhibition. Working from clinical observations of cases of motor alternating strabismus, the author selects 2 types of binocular sensory relations which allow one to differentiate between:- cases of primary alternating strabismus- cases of secondary alternating strabismusThese forms will develop in different ways; in both cases a cure is possible providing that the right treatment is prescribed and once prescribed carefully followed, etc. It is always a case of serious forms of strabismus whose developmental period is spread over several years.According to the authors, the frequency of cases of true primary strabismus is from 1–3%, the frequency of cases of secondary alternating strabismus varies according to the type of therapy practised on cases of monocular strabismus with amblyopia. These latter will become cases of alternating strabismus under the influence of certain types of therapy carried out over several years (penalization, rocking, alternated occlusion, etc...).Experimental data on kittens confirm clinical data; kittens placed in abnormal environments during the sensitive period will show modification in the distribution of cortical cells and the absence of binocular cells (either because the excitation of the two eyes was not simultaneous, or not identical: artificial strabismus, occlusion, opaque glasses). This disturbances become irreversible after a certain period of exposure (a function of age, length of exposure, etc...).It is thus necessary to bear in mind: 1) the iatrogenic risks of certain orthoptic treatments, 2) the necessity for a binocular form of treatment as soon as possible, as once a certain stage is passed, cortical plasticity diminishes and the elaboration of normal binocular relations becomes impossible.

---

     

Effects of Adenosine Agonists on Intraocular Pressure and Aqueous Humor Dynamics in Cynomolgus Monkeys

The effects of single or multiple topical doses of the relatively selective A₁adenosine receptor agonists (R)-phenylisopropyladenosine (R-PIA) and N⁶-cyclohexyladenosine (CHA) on intraocular pressure (IOP), aqueous humor flow (AHF) and outflow facility were investigated in ocular normotensive cynomolgus monkeys. IOP and AHF were determined, under ketamine anesthesia, by Goldmann applanation tonometry and fluorophotometry, respectively. Total outflow facility was determined by anterior chamber perfusion under pentobarbital anesthesia. A single unilateral topical application of R-PIA (20–250 μg) or CHA (20–500 μg) produced ocular hypertension (maximum rise=4.9 or 3.5 mmHg) within 30 min, followed by ocular hypotension (maximum fall=2.1 or 3.6 mmHg) from 2–6 hr. The relatively selective adenosine A₂antagonist 3,7-dimethyl-1-propargylxanthine (DMPX, 320 μg) inhibited the early hypertension, without influencing the hypotension. Neither 100 μg R-PIA nor 500 μg CHA clearly altered AHF. Total outflow facility was increased by 71% 3 hr after 100 μg R-PIA. In conclusion, the early ocular hypertension produced by topical adenosine agonists in cynomolgus monkeys is associated with the activation of adenosine A₂receptors, while the subsequent hypotension appears to be mediated by adenosine A₁receptors and results primarily from increased outflow facility.